swisspartners Advisors’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-83,098
Closed -$11.3M 30
2023
Q3
$11.3M Buy
83,098
+710
+0.9% +$104K 9.97% 2
2023
Q2
$11.1M Sell
82,388
-170
-0.2% -$24.9K 8.96% 2
2023
Q1
$13.2M Sell
82,558
-3,960
-5% -$605K 10.98% 1
2022
Q4
$14M Sell
86,518
-2,082
-2% -$319K 12.48% 1
2022
Q3
$11.9M Sell
88,600
-14,204
-14% -$2.04M 11.7% 1
2022
Q2
$16.3M Buy
102,804
+715
+0.7% +$109K 13.77% 1
2022
Q1
$16.5M Buy
102,089
+505
+0.5% +$73.4K 11.41% 1
2021
Q4
$13.9M Buy
101,584
+540
+0.5% +$63.8K 9.96% 1
2021
Q3
$10.9M Buy
101,044
+19,765
+24% +$2.26M 7.65% 3
2021
Q2
$9.15M Buy
81,279
+5,975
+8% +$673K 7.17% 3
2021
Q1
$8.15M Sell
75,304
-25,905
-26% -$2.77M 7.23% 3
2020
Q4
$10.7M Buy
101,209
+2,160
+2% +$208K 9.4% 2
2020
Q3
$8.68M Sell
99,049
-3,056
-3% -$288K 11.79% 2
2020
Q2
$10M Sell
102,105
-880
-0.9% -$77.5K 12.64% 1
2020
Q1
$7.85M Buy
102,985
+2,081
+2% +$177K 11.04% 2
2019
Q4
$8.93M Buy
+100,904
New +$8.38M 8.75% 4

Other funds holding ABBV

swisspartners Advisors's ABBV Position: Q4 2023 in Review

swisspartners Advisors sold out of AbbVie (ABBV) in Q4 2023, closing a stake of 83,098 shares — an estimated $11.3M sold.

swisspartners Advisors first reported a position in ABBV in Q4 2019 and held it in 16 quarters. The position peaked at $16.5M in Q1 2022. 3,322 funds tracked by Wall St. Rank hold ABBV as of Q4 2023.

  • swisspartners Advisors reported no remaining AbbVie position as of Q4 2023 after selling out during the quarter.
  • swisspartners Advisors sold 83,098 AbbVie shares in Q4 2023, an estimated $11.3M.
  • swisspartners Advisors first reported a position in AbbVie in Q4 2019 and held it in 16 quarters.
  • swisspartners Advisors's AbbVie position peaked at $16.5M in Q1 2022.
  • 3,322 funds tracked by Wall St. Rank held AbbVie as of Q4 2023.

Based on swisspartners Advisors's 13F filing for Q4 2023, filed 6 Feb 2024.